A new era of prescription drugs has seen record numbers of FDA approved drugs enter the market, helping millions fight disease. At the same time, drug prices are soaring, and debates have resonated from Washington and beyond on how to transform health care and reduce spending. How can the health care industry work to make prescription drugs more affordable?
The Atlantic convened top health policy thinkers and practitioners to explore how to foster drug innovation while controlling cost with new approaches like value-based programs on the horizon.
Watch full session videos
To view photos from this event, please visit our Facebook page
- Tuesday, October 03
- 8:10 a.m.WelcomeMargaret Low, President, AtlanticLIVE
- 8:15 a.m.A View from the SenateSenator Amy Klobuchar (D-MN)
With Matt Thompson, Executive Editor, The Atlantic
- 8:40 a.m.Mapping the DebateMatt Eyles, Executive Vice President of Policy and Regulatory Affairs, America’s Health Insurance Plans
Lori Reilly, Executive Vice President, Policy and Research, PhRMA
With Matt Thompson, The Atlantic
- 9:10 a.m.A View from the HouseRepresentative Patrick Meehan (R-PA)
With Kathleen Koch, Author and Journalist
- 9:35 a.m.Super Spending: The New Normal?*
Produced by our underwriter Express ScriptsSteve Miller, Chief Medical Officer, Express Scripts
* This session was produced by our underwriter and not by The Atlantic’s editorial team.
- 9:45 a.m.Personalizing PrescriptionsPeter Bach, Director,Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Michael Pishvaian, Director, Phase I Clinical Trial Program, Georgetown Lombardi Comprehensive Cancer Center
Michael Sapienza, Chief Executive Officer, Colon Cancer Alliance
With Olga Khazan, Staff Writer, The Atlantic
- 10:15 a.m.Closing ThoughtsMargaret Low, AtlanticLIVE